Emotional and cognitive empathy in patients with non-epileptic seizures

Although the incidence of non-epileptic seizures (NES) of approximately 1,5 – 4,9/100 000 per year and the prevalence of 2–33/100 000 do not appear to be particularly high, patients with NES are quite prevalent in epilepsy centers, where 20–50 % of patients are diagnosed with NES [1–4]. Nonetheless, the latency between manifestation and diagnosis of 7.2 years is high [5]. Patients with NES have similar social and occupational impairments as epilepsy patients [6]. Economically, NES are reflected as a burden ...

Seguir leyendo →
0

Institutional Pediatric Convulsive Status Epilepticus Protocol Decreases Time to First and Second Line Anti-Seizure Medication Administration

Convulsive status epilepticus (CSE) is defined as continuous seizure activity of greater than five minutes or multiple seizures in that time period without return to clinical baseline. [1] CSE is one of the most common pediatric neurologic emergencies in the emergency department (ED) [2]. Short-term mortality of CSE ranges from 2.7%-5.2%, and is as high as 5-8% for patients requiring intensive care. Those who survive have a higher risk for developing negative long-term outcomes including epilepsy, cognitive impairment, hippocampal injury, ...

Seguir leyendo →
0

Antibiotic-induced epileptic seizures: mechanisms of action and clinical considerations

There exists a considerable body of literature on the increased risk of developing epileptic seizures as an adverse effect of antibiotic therapy. β-lactams and fluoroquinolones are most frequently associated with central nervous system toxicity and neurological side effects [1]. Although infrequent, other classes of antibiotics have also been reported to induce neurotoxicity or trigger epileptic seizures. Gamma-aminobutyric acid (GABA) receptor antagonism is a common mechanism shared by penicillins, cephalosporins, imipenem, and fluoroquinolones [2,3].

Seguir leyendo →
0

Sources of lamotrigine pharmacokinetic variability: A systematic review of population pharmacokinetic analyses

Lamotrigine (LTG), a new generation antiepileptic drug (AED), is approved as adjunctive therapy for partial seizures as well as generalized seizures of Lennox-Gastaut syndrome in adult and pediatric patients aged ≥ 2 years. In addition, the drug is indicated for conversion from enzyme-inducing AED or valproate to monotherapy in adults with partial seizures and is also used for the maintenance treatment of bipolar I disorder [1]. It is also investigated for its use for the treatment of treatment-resistant depressive disorders ...

Seguir leyendo →
0

Comment on “Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19”

Monti and colleagues [1] described a patient who developed psychiatric symptoms followed by refractory status epilepticus caused by anti N-D-Methyl-Aspartate receptor (NMDAr) encephalitis. Despite the lack of lung involvement, the patient resulted positive for SARS-CoV-2 infection. Recently, another case of anti-NMDAr encephalitis with prominent psychiatric symptoms during symptomatic SARS-CoV-2 infection has been reported by Panariello and colleagues [2]. NMDAr encephalitis represents one of the most frequent cause of autoimmune encephalitis and, in a minority of patients, it may be triggered ...

Seguir leyendo →
0
Página 98 de 194 «...70809096979899100...»